Leiden University Medical Center, Dept. Infectious Diseases

LUMC is a modern university medical center for research, education and patient care with a high quality profile and a strong scientific orientation. Its unique research practice, ranging from pure fundamental medical research to applied clinical research, places LUMC among the world top. This enables LUMC to offer patient care and education that is in line with the latest international insights and standards – and helps it to improve medicine and healthcare both internally and externally. LUMC’s mission is to dissect host immunological and genetic mechanisms of protective and impaired immunity in infectious diseases. Its aim is to design optimal therapeutic (e.g. immune modulation) and preventive (e.g. vaccination) intervention strategies, by establishing relevant and robust biomarkers of disease and protection (e.g. immunodiagnostics and monitoring) and developing and testing new vaccines, and new vaccination strategies. For more please see: https://www.lumc.nl/org/infectieziekten/Research/?setlanguage=English&setcountry=en

Role in the TRANSVAC project

​

Main staff involved in TRANSVAC

Marielle C. Haks and Tom H.M. Ottenhoff

The Facility

We provide access to a semi-high-throughput assay which is reliable, quantitative, robust, inexpensive, user friendly, and capable of profiling up to 200 genes using as little as 100 ng per sample. It allows the analysis of host immune gene expression in relation to vaccination, infection, disease or therapy in larger cohorts. We have incorporated genes that assess various compartments of the human immune response, which play key roles in inducing and skewing immune reactivity. Expression profiles can also be determined following relevant antigenic in vitro stimulation using whole blood or PBMC-based assays with samples derived from individuals/patients collected at different time points post vaccination /immunisation. The facility is already used by other EU projects.

TNA or Training provided

Modality of access under this proposal: Users will provide either samples or ready-isolated RNA and will decide how many genes will be profiled. Analysis of gene expression profiles can be carried out by the users, or by the facility. Users can be trained at the facility if needed. A maximum of seven projects can be supported under this service, depending on sample numbers. Support offered under this proposal: Extended multiplex transcriptome profiling (dcRT-MLPA) of innate, adaptive and inflammatory immune-response signalling gene signatures. In mutual agreement with the facility, users will decide the scope of the service, including the number of genes to be profiled.

Description

 

 

 

Description

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N° 730964.

Be the first to know about the upcoming application calls, follow European Vaccine Initiative on:

  • LinkedIn Social Icon
  • Twitter Social Icon

Designed by European Vaccine Initiative